Your browser doesn't support javascript.
loading
Telehealth use and perceptions among prostate cancer survivors.
Chen, Luke W; Usinger, Deborah S; Katz, Aaron J.
Afiliação
  • Chen LW; Department of Radiation Oncology, University of Kansas Cancer Center, Kansas City, Kansas, USA.
  • Usinger DS; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Katz AJ; Department of Radiation Oncology, University of Kansas Cancer Center, Kansas City, Kansas, USA.
Cancer Med ; 12(16): 17308-17312, 2023 08.
Article em En | MEDLINE | ID: mdl-37455582
BACKGROUND: Reasons underlying disparities in telehealth use among cancer survivors are unknown. METHODS: We surveyed a sociodemographically diverse population-based cohort of 487 prostate cancer survivors regarding their use and perceptions of telehealth during the COVID-19 pandemic. RESULTS: Overall, only 28.5% of survivors had used telehealth at the time of survey and just 10% felt care through telehealth is comparable to that of an in-person visit. Still, over 55% felt telehealth is a good option for initial consultations or basic care and 15% felt more likely to use telehealth since the pandemic. After adjusting for other socioeconomic factors, survivors with lower education (≤high school vs. any college) had marginally lower use of telehealth (risk ratio [RR], 0.65 [95% CI, 0.42-1.01]) and lower probability of feeling more likely to use telehealth since the pandemic (RR, 0.39 [95% CI, 0.20-0.77]). CONCLUSIONS: Differences in survivor perceptions of telehealth by education level highlight new insights underlying disparities in telehealth use and potential targets for interventions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Telemedicina / Sobreviventes de Câncer / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Telemedicina / Sobreviventes de Câncer / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article